A €5 million national health scheme will provide free weight-loss drugs to patients with obesity and diabetes, aiming to reduce the burden of chronic illness and improve long-term health outcomes. The initiative targets individuals whose conditions place them at higher risk of cardiovascular disease, complications, and reduced quality of life, with eligibility based on clinical criteria set by health authorities. By covering the cost of approved weight-loss medication, the scheme removes financial barriers that often prevent patients from accessing treatment, particularly those who have not seen sufficient results from lifestyle changes alone.
Health officials stated that the program forms part of a wider strategy to tackle obesity and type 2 diabetes through medical intervention combined with support services such as dietary guidance and monitoring. The medication will be prescribed following assessment by doctors to ensure it is suitable for each patient, and treatment will be reviewed regularly to track effectiveness and manage any side effects. The €5 million allocation is expected to cover thousands of patients in the initial phase, with data collected to evaluate the impact on weight reduction, blood sugar control, and hospital admissions.
The scheme reflects growing recognition that obesity is a complex medical condition requiring structured treatment options beyond personal responsibility. Authorities emphasized that the free drugs are not a standalone solution but a tool to help patients who meet specific medical thresholds regain control of their health. Rollout will begin through public health clinics and hospitals, with the program monitored to determine whether expanded funding is warranted in future budgets.
